See more : Chuy’s Holdings, Inc. (CHUY) Income Statement Analysis – Financial Results
Complete financial analysis of Codexis, Inc. (CDXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codexis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LXP Industrial Trust (LXP-PC) Income Statement Analysis – Financial Results
- ES-CON JAPAN Ltd. (8892.T) Income Statement Analysis – Financial Results
- Invivyd, Inc. (IVVD) Income Statement Analysis – Financial Results
- NexGen Energy Ltd. (NXG.AX) Income Statement Analysis – Financial Results
- Viva Gold Corp. (VAUCF) Income Statement Analysis – Financial Results
Codexis, Inc. (CDXS)
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.14M | 138.59M | 104.75M | 69.06M | 68.46M | 60.59M | 50.02M | 48.84M | 41.80M | 35.31M | 31.92M | 88.30M | 123.87M | 107.10M | 82.91M | 50.48M | 25.33M | 12.13M |
| Cost of Revenue | 12.81M | 38.03M | 22.21M | 13.74M | 15.63M | 12.62M | 14.33M | 9.75M | 6.59M | 9.73M | 14.55M | 30.65M | 41.78M | 27.98M | 16.68M | 13.19M | 8.32M | 1.81M |
| Gross Profit | 57.33M | 100.56M | 82.55M | 55.31M | 52.83M | 47.97M | 35.70M | 39.08M | 35.22M | 25.58M | 17.37M | 57.65M | 82.08M | 79.12M | 66.23M | 37.29M | 17.01M | 10.32M |
| Gross Profit Ratio | 81.74% | 72.56% | 78.80% | 80.10% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | 73.87% | 67.16% | 85.11% |
| Research & Development | 58.89M | 80.10M | 55.92M | 44.19M | 33.87M | 29.98M | 29.66M | 22.23M | 20.67M | 22.76M | 31.61M | 56.79M | 61.05M | 52.41M | 54.73M | 45.55M | 35.64M | 17.26M |
| General & Administrative | 52.95M | 51.87M | 49.02M | 34.75M | 31.00M | 28.79M | 28.31M | 24.92M | 22.02M | 21.64M | 26.41M | 30.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 300.00K | 300.00K | 300.00K | 300.00K | 500.00K | 500.00K | 700.00K | 500.00K | 300.00K | 300.00K | 500.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.25M | 52.17M | 49.32M | 35.05M | 31.50M | 29.29M | 29.01M | 25.42M | 22.32M | 21.94M | 26.91M | 31.38M | 36.94M | 33.84M | 29.87M | 35.71M | 19.71M | 11.88M |
| Other Expenses | 13.27M | 124.00K | 1.15M | -156.00K | -656.00K | -291.00K | -92.00K | -94.00K | -168.00K | -234.00K | 24.74M | -326.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.40M | 132.27M | 105.24M | 79.23M | 65.38M | 59.27M | 58.67M | 47.65M | 42.99M | 44.69M | 58.51M | 88.16M | 97.99M | 86.25M | 84.60M | 81.26M | 55.36M | 29.14M |
| Cost & Expenses | 138.21M | 170.30M | 127.45M | 92.98M | 81.01M | 71.89M | 72.99M | 57.40M | 49.57M | 54.42M | 73.07M | 118.81M | 139.77M | 114.23M | 101.27M | 94.45M | 63.68M | 30.94M |
| Interest Income | 4.17M | 1.44M | 459.00K | 405.00K | 1.29M | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 60.00K | 252.00K | 273.00K | 166.00K | 180.00K | 1.54M | 1.49M | 742.00K |
| Interest Expense | 0.00 | 1.44M | 0.00 | 0.00 | 0.00 | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 304.00K | 274.00K | 675.00K | 1.20M | 2.04M | 2.37M | 2.53M | 724.00K |
| Depreciation & Amortization | 9.92M | 10.25M | 5.95M | 4.55M | 4.77M | 1.15M | 1.04M | 4.55M | 5.41M | 6.69M | 10.32M | 12.42M | 11.47M | 8.31M | 6.13M | 4.56M | 2.88M | 2.39M |
| EBITDA | -49.28M | -23.07M | -16.75M | -19.37M | -7.99M | -10.15M | -21.93M | -4.02M | -2.36M | -12.64M | -31.07M | -18.17M | -4.84M | 681.00K | -12.06M | -37.87M | -35.67M | -15.69M |
| EBITDA Ratio | -70.26% | -20.60% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.71% | -34.56% | -3.36% | 1.26% | -14.54% | -75.03% | -134.09% | -129.36% |
| Operating Income | -68.07M | -31.71M | -22.70M | -23.92M | -12.55M | -11.30M | -22.97M | -8.56M | -7.77M | -19.11M | -41.15M | -30.51M | -15.91M | -7.12M | -18.37M | -43.97M | -38.34M | -18.82M |
| Operating Income Ratio | -97.04% | -22.88% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.90% | -34.56% | -12.84% | -6.65% | -22.15% | -87.11% | -151.36% | -155.16% |
| Total Other Income/Expenses | -8.10M | 1.57M | 1.61M | 249.00K | 631.00K | 380.00K | 55.00K | -34.00K | -149.00K | -216.00K | -244.00K | -74.00K | -402.00K | -1.03M | -1.86M | -827.00K | -1.04M | 18.00K |
| Income Before Tax | -76.17M | -33.32M | -21.09M | -23.67M | -11.92M | -10.92M | -22.92M | -8.60M | -7.92M | -19.33M | -41.39M | -30.59M | -16.31M | -8.16M | -20.22M | -44.80M | -39.39M | -18.80M |
| Income Before Tax Ratio | -108.59% | -24.04% | -20.13% | -34.28% | -17.41% | -18.01% | -45.81% | -17.61% | -18.94% | -54.74% | -129.66% | -34.64% | -13.17% | -7.62% | -24.39% | -88.75% | -155.47% | -155.01% |
| Income Tax Expense | 69.00K | 276.00K | 189.00K | 339.00K | 17.00K | -37.00K | 81.00K | -40.00K | -338.00K | -256.00K | -87.00K | 270.00K | 241.00K | 384.00K | 66.00K | 327.00K | -408.00K | -127.00K |
| Net Income | -76.24M | -33.59M | -21.28M | -24.01M | -11.94M | -10.88M | -23.00M | -8.56M | -7.58M | -19.07M | -41.30M | -30.86M | -16.55M | -8.54M | -20.29M | -45.13M | -38.98M | -18.67M |
| Net Income Ratio | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | -89.40% | -153.86% | -153.96% |
| EPS | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| EPS Diluted | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| Weighted Avg Shares Out | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
| Weighted Avg Shares Out (Dil) | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
Codexis to Report Third Quarter 2024 Financial Results on October 31
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024...
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis,...
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors....
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences.
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September...
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors....
Codexis Publishes FY2023 Sustainability Disclosures
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research Kevin Norrett - COO Sri Ryali -...
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports